CN1395960A - Antineoplastic Chinese medicine - Google Patents
Antineoplastic Chinese medicine Download PDFInfo
- Publication number
- CN1395960A CN1395960A CN02135300A CN02135300A CN1395960A CN 1395960 A CN1395960 A CN 1395960A CN 02135300 A CN02135300 A CN 02135300A CN 02135300 A CN02135300 A CN 02135300A CN 1395960 A CN1395960 A CN 1395960A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- water
- weight
- tumor
- baths
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
An anticancer Chinese medicine for treating lung cancer and the cancer in digestive tract is prepared from 7 Chinese medicinal materials including astragalus root, seaweed, white atractylodes rhizome, lindera root, etc. in a certain proportion. Its advantages are high tumor suppressing action and low toxic by-effect.
Description
The present invention relates to a kind of Chinese medicine, particularly relate to a kind of anti-tumor compound Chinese medicine.
Malignant tumor is the disease of serious harm human health, existing antitumor drug mostly is cytotoxic drug greatly, such medicine is in killing tumor cell, the human normal cell also there is infringement, serious destruction immunity of organism organ, make tumor patient quality of life low, increase in life span descends.China's Chinese medicine has long clinical application basis, press down aspects such as tumor, immunostimulant in treating the poisonous disease with poisonous drugs, immunity and developed many PTS, but most tumor killing effect is not good.
The purpose of this invention is to provide a kind of effective tumor suppression medicine, it can remedy the above-mentioned deficiency of existing medicine.
A kind of antineoplastic Chinese medicine is characterized in that containing the Radix Astragali, Polyporus, the Rhizoma Atractylodis Macrocephalae, Sargassum, the Radix Linderae, Endothelium corneum, Herba Hedyotidis Diffusae, and the ratio of their parts by weight is: 50-100: 50-100: 50-100: 50-100: 50-100: 20-50: 20-50.
A kind of antitumor preparation method of Chinese medicine, it is characterized in that each Chinese medicine component is pulverized is coarse powder, 60 ℃ of-80 ℃ of water-baths of diluted acid water with 8-12 times of weight are extracted, filter, 60 ℃ of-80 ℃ of water-baths of the diluted alkaline water of 8-12 times of weight of medicinal residues reuse are extracted, merge the soda acid extracting solution, concentrating under reduced pressure adds to compose and expects to make granule.
Process for preparing medicine of the present invention is simple to operate, the cycle is short, active constituent content is high, and cost of manufacture is low; This medicine can significantly improve body's immunity, obviously improves the life quality of tumour patient.
Below by embodiment the present invention is described.
Take by weighing Radix Astragali 75g, Polyporus 75g, Rhizoma Atractylodis Macrocephalae 75g, Sargassum 75g, Radix Linderae 75g, Endothelium corneum 35g, Herba Hedyotidis Diffusae 35g, it is coarse powder (20-80 order) that each Chinese medicine component is pulverized, 80 ℃ of water-baths of diluted acid water (pH2-4) with 10 times of weight are extracted twice, filter, 80 ℃ of water-baths of the diluted alkaline water (pH7.5-9.5) of 8-12 times of weight of medicinal residues reuse are extracted twice, merge the soda acid extracting solution, concentrating under reduced pressure, adding dextrin, Icing Sugar excipient are made granule.The preparation of making is an index with the content of active ingredient astragaloside and total polysaccharides, adopts high performance liquid chromatogram and phenolsulfuric acid method to carry out quality control standard.
Chinese medicine of the present invention is formed by the principle of Chinese traditional treatment tumor.Radix Astragali tonifying Qi and lifting yang wherein has tonification castering action preferably for the deficiency of vital energy of spleen lung, stops the poly-merit that inducing diuresis to remove edema can be arranged because of insufficiency of the spleen fortune water is wet; But the Rhizoma Atractylodis Macrocephalae is air making-up and spleen enlivening, dampness, diuretic also, for this reason Fang monarch drug.Sargassum is salty-cold, antiinflammatory softening the hard mass, broken eliminating stagnation gas; Polyporus diuresis, eliminating dampness by diuresis, that expectorant is given birth to is passive, for this reason Fang ministerial drug.The Herba Hedyotidis Diffusae heat-clearing and toxic substances removing, promoting blood circulation and stopping pain can be separated expectorant blood coagulation stasis of blood poison and accumulate, and the merit of inducing diuresis to remove edema is arranged, for this reason Fang adjuvant drug.The Endothelium corneum activating the spleen helps digestion, in case stagnation of dampness due to deficiency of the spleen, and failing of the spleen to transport and cause dyspepsia; The hot Wen Xiang of the Radix Linderae scurries, on walk the spleen lung, the reason breast abdomen stagnation of QI, promoting the circulation of QI to relieve pain are assigned kidney and bladder, warming kidney for dispelling cold, sensible yang-energy so that part of the body cavity below the umbilicus, housing the bladder, kidneys and bowels water channel is unobstructed, has both helped absorption, the running of medicine, the anti-again sweet stagnant cold of all medicines is cold, for this reason Fang messenger drug.
In sum, the Radix Astragali is mended the gas of strengthening spleen and lung, and invigorating spleen to remove dampness, the Rhizoma Atractylodis Macrocephalae help its power; The Sargassum eliminating phlegm and softening indurated mass, broken eliminating stagnation gas, Polyporus is strengthened its usefulness; The Herba Hedyotidis Diffusae heat-clearing and toxic substances removing, promoting blood circulation and stopping pain; Endothelium corneum, the Radix Linderae are transferred sharp taste, and sensible yang-energy had both helped the absorptions running of medicine, and the anti-again sweet stagnant cold of all medicines is cold, and the group medicine of full side is auxilliary mutually to be usefulness, focus on QI invigorating, spleen invigorating, reduce phlegm, eliminating stagnation.
Medicine of the present invention has QI invigorating, spleen invigorating, reduces phlegm, the eliminating stagnation effect, by the pharmacodynamics requirement of the anticancer centralizing function of Chinese medicine, with mice S
180Solid tumor, mice Emhorn ascitic type tumor are that model has been observed inhibition and the life prolongation effect of said preparation to tumor growth; And observe its influence to tumor-bearing mice spleen antibody-producting cell, Turnover of Mouse Peritoneal Macrophages phagocytic function and tumor-bearing mice thymus, spleen weight.The result shows: said preparation can significantly suppress mice S
180The solid tumor growth prolongs ascitic type mice with tumor life span; And obviously increase the weight of tumor-bearing mice immune organ, and improve the Turnover of Mouse Peritoneal Macrophages phagocytic function, promote the generation of tumor-bearing mice spleen antibody-producting cell simultaneously.
Clinical drug of the present invention cooperates radiotherapy or chemotherapy according to different sick sensitivity and different situations of planting radiotherapy, chemotherapy, and one month is a course of treatment.Put, still can continue to take behind the end of chemotherapy, generally take 2-6 the course of treatment.Treat 20 examples altogether, pulmonary carcinoma 5 examples wherein, human primary gastrointestinal cancers 15 examples, effective percentage is pressed the CR+PR statistics, and life quality is pressed Ka Shi scoring statistics, and curative effect and life quality analysis all are higher than the radiation alone and the chemotherapy group of general bibliographical information, experimental results show that this side has tumour inhibiting rate preferably, there is no obvious toxic and side effects.
Claims (2)
1. an antineoplastic Chinese medicine is characterized in that containing the Radix Astragali, Polyporus, the Rhizoma Atractylodis Macrocephalae, Sargassum, the Radix Linderae, Endothelium corneum, Herba Hedyotidis Diffusae, and the ratio of their parts by weight is: 50-100: 50-100: 50-100: 50-100: 50-100: 20-50: 20-50.
2. antitumor preparation method of Chinese medicine, it is characterized in that each Chinese medicine component is pulverized is coarse powder, 60 ℃ of-80 ℃ of water-baths of diluted acid water with 8-12 times of weight are extracted, filter, 60 ℃ of-80 ℃ of water-baths of the diluted alkaline water of 8-12 times of weight of medicinal residues reuse are extracted, merge the soda acid extracting solution, concentrating under reduced pressure adds to compose and expects to make granule.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB02135300XA CN1175876C (en) | 2002-08-02 | 2002-08-02 | Antineoplastic Chinese medicine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB02135300XA CN1175876C (en) | 2002-08-02 | 2002-08-02 | Antineoplastic Chinese medicine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1395960A true CN1395960A (en) | 2003-02-12 |
CN1175876C CN1175876C (en) | 2004-11-17 |
Family
ID=4748125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB02135300XA Expired - Fee Related CN1175876C (en) | 2002-08-02 | 2002-08-02 | Antineoplastic Chinese medicine |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1175876C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103520360A (en) * | 2013-10-16 | 2014-01-22 | 中国海洋大学 | Chinese herbal compound preparation, and preparation method and application of Chinese herbal compound preparation |
CN104716709A (en) * | 2006-10-31 | 2015-06-17 | 索尼株式会社 | Electronic apparatus, charging method therefor, and battery |
-
2002
- 2002-08-02 CN CNB02135300XA patent/CN1175876C/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104716709A (en) * | 2006-10-31 | 2015-06-17 | 索尼株式会社 | Electronic apparatus, charging method therefor, and battery |
CN103520360A (en) * | 2013-10-16 | 2014-01-22 | 中国海洋大学 | Chinese herbal compound preparation, and preparation method and application of Chinese herbal compound preparation |
Also Published As
Publication number | Publication date |
---|---|
CN1175876C (en) | 2004-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104225441A (en) | Traditional Chinese medicine composition for treating stomach trouble and preparation method of granules and capsules of traditional Chinese medicine composition | |
CN102824445B (en) | Traditional Chinese medicine composition for treating duodenal ulcer | |
CN103432265A (en) | Traditional Chinese medicinal composition preparation for treating fever in children and preparation method thereof | |
CN1175876C (en) | Antineoplastic Chinese medicine | |
CN102100849B (en) | Chinese medicine preparation for treating lumbar disc herniation and preparation method thereof | |
CN101327293B (en) | Capsules for treating peptic ulcer and preparation method thereof | |
CN101129896B (en) | Chinese medicinal herb agentia for treating tumour disease | |
CN106822733B (en) | Ointment for treating precancerous lesion of chronic atrophic gastritis and preparation method thereof | |
CN101979035A (en) | Medicament for treating gynecological abnormal leucorrhea | |
CN1742866A (en) | Anti-cancer Chinese medicine capsule preparation | |
CN102370758A (en) | Antitumor traditional Chinese medicine | |
CN108543036A (en) | A kind of antitumor drug and preparation method thereof | |
CN109602790A (en) | A kind of Chinese medicine composition that treating malignant pleural effusion with lung cancer and its preparation and application | |
CN111514237B (en) | Traditional Chinese medicine composition for treating viral myocarditis and preparation method thereof | |
CN105687474A (en) | Preparation for cancer patient to take during chemotherapy period and preparation method | |
CN101011512A (en) | Medicine for treating digestive tract tumour and its preparing process | |
CN101468144B (en) | Chinese medicine compound preparation for treating ventricular premature beat | |
CN101766718A (en) | Drug combination for treating chronic cholecystitis and preparation method thereof | |
CN101194940A (en) | Anti-inflammation medicament for treating toothache and preparation method thereof | |
CN1110589A (en) | Pill for treating splenico or gastric vital energy deficiency type chronic superficial, atrophic gastritis | |
CN115192662A (en) | Traditional Chinese medicine composition and medicine for treating tumors | |
CN105106468A (en) | Antineoplastic traditional Chinese medicine composition for medical oncology | |
CN1261146C (en) | Plaster for treating hyperplasia of mammary glands | |
CN100364586C (en) | Medicine for treating digestive tract tumor and its preparation method | |
CN103230490B (en) | Traditional Chinese medicine pulvis for treating liver neoplasms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |